November 4, 2025 — InspireMD, Inc. (Nasdaq: NSPR) reported its third-quarter financial and operating results, highlighting the U.S. commercial launch of the CGuard® Prime carotid stent system and a 39% increase in total revenue to $2.5 million compared to $1.8 million in the same period last year.
The company completed over 100 U.S. carotid procedures across leading hospitals and appointed Peter A. Soukas, M.D., as Chief Medical Officer and Dan Dearen as Audit Committee Chairman. U.S. revenue for the quarter was $497,000, with international revenue at $2.0 million, driven by CGuard Prime sales, international market penetration, and favorable foreign exchange rates.
Gross profit increased to $864,000 from $414,000 year-over-year, while operating expenses rose by 57% to $13.9 million due to U.S. personnel expansion and the establishment of a U.S. headquarters. Net loss for the quarter was $12.7 million, or $0.17 per share, compared to $7.9 million, or $0.16 per share, in 2024. Cash and marketable securities totaled $63.4 million as of September 30, 2025.
Marvin Slosman, CEO of InspireMD, noted strong growth across all geographies and expressed confidence in the company’s team and technology to deliver immense value. InspireMD will host a conference call at 8:30 a.m. ET today to discuss the results.
Investor Contacts:
Webb Campbell
Gilmartin Group LLC
Webb@gilmartinir.com
investor-relations@inspiremd.com
Source: InspireMD, Inc.
